CoChat

The Immunology of Psoriasis-Current Concepts in Pathogenesis

Open access
Sieminska, Izabela, Pieniawska, Monika, Grzywa, Tomasz M. · 2024 · Clinical Reviews in Allergy & Immunology

The DOI matches its Crossref record; 308 of the 308 references it cites were found in a registry or an index.

Abstract

Psoriasis is one of the most common inflammatory skin diseases with a chronic, relapsing-remitting course. The last decades of intense research uncovered a pathological network of interactions between immune cells and other types of cells in the pathogenesis of psoriasis. Emerging evidence indicates that dendritic cells, T H 17 cells, and keratinocytes constitute a pathogenic triad in psoriasis. Dendritic cells produce TNF-α and IL-23 to promote T cell differentiation toward T H 17 cells that produce key psoriatic cytokines IL-17, IFN-γ, and IL-22. Their activity results in skin inflammation and activation and hyperproliferation of keratinocytes. In addition, other cells and signaling pathways are implicated in the pathogenesis of psoriasis, including T H 9 cells, T H 22 cells, CD8 + cytotoxic cells, neutrophils, γδ T cells, and cytokines and chemokines secreted by them. New insights from high-throughput analysis of lesional skin identified novel signaling pathways and cell populations involved in the pathogenesis. These studies not only expanded our knowledge about the mechanisms of immune response and the pathogenesis of psoriasis but also resulted in a revolution in the clinical management of patients with psoriasis. Thus, understanding the mechanisms of immune response in psoriatic inflammation is crucial for further studies, the development of novel therapeutic strategies, and the clinical management of psoriasis patients. The aim of the review was to comprehensively present the dysregulation of immune response in psoriasis with an emphasis on recent findings. Here, we described the role of immune cells, including T cells, B cells, dendritic cells, neutrophils, monocytes, mast cells, and innate lymphoid cells (ILCs), as well as non-immune cells, including keratinocytes, fibroblasts, endothelial cells, and platelets in the initiation, development, and progression of psoriasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12016-024-08991-7

Cites

308 of 308 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Dysregulation of immune response in psoriasis. Psoriasis may be triggered by different factors, including skin injury (Koebner phenomenon), infection, drugs, and autoantigens in predisposed individuals. In the early phase of psoriasis, neutrophils infiltrate the skin and release neutrophils extracellular traps (NETs), exosomes, metalloproteinase 9 (MMP9), and IL-17. Activated keratinocytes (KCs) have increased proliferative capacity and produce a variety of pro-inflammatory factors, including chemokines, antimicrobial peptides (AMPs), and alarmins. Dendritic cells (DCs) are activated by toll-like receptors (TLRs) ligands and AMPs which initiate T cell immune response. DCs activate a variety of T cells, including IL-17-producing TH17 and Tc17 cells, IL-9-producing TH9 cells, IFN-γ-producing TH1 cells, and IL-22-producing TH22 cells. Moreover, DCs and Langerhans cells (LCs) can present autoantigens stimulating autoreactive T cells. The impaired skin microbiome activates γδ T cells that produce IL-17 and IL-1β. In the late phase of inflammation, psoriatic lesions are characterized by the profound infiltration of immune cells, increased concentrations of multiple cytokines and chemokines, and hyperproliferation of KCs. Moreover, increased angiogenesis and endothelial cells activated by psoriatic cytokines facilitate the infiltration of immune cells into inflamed skin. Created with Biorender.com
Fig. 1 Dysregulation of immune response in psoriasis. Psoriasis may be triggered by different factors, including skin injury (Koebner phenomenon), infection, drugs, and autoantigens in predisposed individuals. In the early phase of psoriasis, neutrophils infiltrate the skin and release neutrophils extracellular traps (NETs), exosomes, metalloproteinase 9 (MMP9), and IL-17. Activated keratinocytes (KCs) have increased proliferative capacity and produce a variety of pro-inflammatory factors, including chemokines, antimicrobial peptides (AMPs), and alarmins. Dendritic cells (DCs) are activated by toll-like receptors (TLRs) ligands and AMPs which initiate T cell immune response. DCs activate a variety of T cells, including IL-17-producing TH17 and Tc17 cells, IL-9-producing TH9 cells, IFN-γ-producing TH1 cells, and IL-22-producing TH22 cells. Moreover, DCs and Langerhans cells (LCs) can present autoantigens stimulating autoreactive T cells. The impaired skin microbiome activates γδ T cells that produce IL-17 and IL-1β. In the late phase of inflammation, psoriatic lesions are characterized by the profound infiltration of immune cells, increased concentrations of multiple cytokines and chemokines, and hyperproliferation of KCs. Moreover, increased angiogenesis and endothelial cells activated by psoriatic cytokines facilitate the infiltration of immune cells into inflamed skin. Created with Biorender.comCC BY · PubMed Central
Fig. 2 Cytokine network and therapeutic targets in psoriasis. Immune response in psoriasis is associated with the activation of type 1, type 17, and type 22 pathways and innate inflammatory pathways. These signaling pathways induce the expression of different genes involved in the regulation of psoriatic inflammation (orange boxes). Several biological drugs targeting key psoriatic cytokines (indicated in red) or small molecule inhibitors of downstream cytokine signaling were developed and approved by the FDA. PsA, psoriasis arthritis; PP, pustular psoriasis. Created with Biorender.com
Fig. 2 Cytokine network and therapeutic targets in psoriasis. Immune response in psoriasis is associated with the activation of type 1, type 17, and type 22 pathways and innate inflammatory pathways. These signaling pathways induce the expression of different genes involved in the regulation of psoriatic inflammation (orange boxes). Several biological drugs targeting key psoriatic cytokines (indicated in red) or small molecule inhibitors of downstream cytokine signaling were developed and approved by the FDA. PsA, psoriasis arthritis; PP, pustular psoriasis. Created with Biorender.comCC BY · PubMed Central
Fig. 3 The role of immune cells in psoriasis. The key populations of immune cells and their functions in the regulation of psoriatic inflammation. Created with Biorender.com
Fig. 3 The role of immune cells in psoriasis. The key populations of immune cells and their functions in the regulation of psoriatic inflammation. Created with Biorender.comCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 308 references

Cited by

Metadata

Authors
Sieminska, I., Pieniawska, M., & Grzywa, T. M.
Affiliations
  • Institute of Human Genetics (PL)
  • Children's Hospital of Philadelphia (US)
Corresponding author
Grzywa, Tomasz M.
Venue
Clinical Reviews in Allergy & Immunology
Published
2024-04-20
Volume
66
Issue
2
Pages
164-191
ISSN
  • 1080-0549 (ISSN-L)
  • 1559-0267
OpenAlex
W4394989398
Cited by
346
References
308
Citations by year
2026: 187 · 2025: 140 · 2024: 19
FWCI
15.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Reviews in Allergy & Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Narodowe Centrum Nauki (2021/41/N/NZ6/02774)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
Keywords
psoriasis, psoriasis pathogenesis, dendritic cells, Th17 cells, keratinocytes, IL-23, TNF-α, IL-17, IL-22, Th9 cells, Th22 cells, cytotoxic T lymphocytes, neutrophils, γδ T cells, innate lymphoid cells, mast cells, non-immune cells, skin inflammation, immune dysregulation
MeSH terms
Animals, Dendritic Cells, Humans, Psoriasis, Skin, Signal Transduction, Keratinocytes, T-Lymphocyte Subsets, Cytokines, Th17 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.